Markets

Why Shares of Novavax Inc Are Surging Higher Today

Shares of (NASDAQ: NVAX) a clinical-stage biopharmaceutical company focused on creating vaccines for infectious diseases, jumped more than 17% in early trading today on heavy volume after the company released updated clinical information on its Respiratory Syncytial Virus, or RSV, vaccine.

What: Shares of Novavax (NASDAQ: NVAX) a clinical-stage biopharmaceutical company focused on creating vaccines for infectious diseases, jumped more than 17% in early trading today on heavy volume after the company released updated clinical information on its Respiratory Syncytial Virus, or RSV, vaccine.

So what: Yesterday, the company held its third annual analyst and investor meeting, at which time the company reported positive top line data from its phase 2 clinical trial of its RSV F vaccine's ability to protect infants via maternal immunization. In the trial, the company reported that the vaccine was safe, transferred effectively from mother to infant, and generated a significant antibody response.

In a separate announcement, Novavax revealed that the Bill & Melinda Gates Foundation awarded the company with a grant worth up to $89 million to support further development of its RSV F Vaccine. The company plans to initiate Phase 3 clinical trial during the first quarter of 2016.

Now what: While this clinical update was certainly positive, the market has manhandled Novavax's stock over the past couple days. The market initially bid the stock up after the news was released yesterday, then went on to sell shares off hard. Today's jump appears to be the market coming to its senses and is so far sending shares higher on the positive announcement.

RSV remains a very serious problem around the world that hits infants and young children worldwide especially hard. An estimated 64 million patients contract the disease every year, and more than 160,000 of them actually die as a result. If Novavax is successful in developing a vaccine, it could certainly go a long way to boosting the health of millions of people around the world.

The market's recent craziness has caused shares to fall nearly 35% in the past month alone, but considering these great results and the rest of the company's pipeline , it might be a good time to considering adding this name to the more speculative portion of your portfolio.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article Why Shares of Novavax Inc Are Surging Higher Today originally appeared on Fool.com.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVAX

Other Topics

Stocks

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More